Juvenile Myasthenia Gravis (JMG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Juvenile Myasthenia Gravis (JMG) Market Outlook

Thelansis’s “Juvenile Myasthenia Gravis (JMG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Juvenile Myasthenia Gravis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Juvenile Myasthenia Gravis (JMG) Overview

Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder affecting the neuromuscular junction, leading to either ocular manifestations or generalized weakness in individuals under the age of 18. The onset of this condition can occur either before the age of 12 (prepubertal) or after the age of 12 (postpubertal). The primary characteristic of MG is muscle weakness that worsens with exertion. The initial presentation of the disease may be acute or subacute, typically following a chronic course with periods of remission and relapses. In prepubertal children, the ocular presentation is more common and is characterized by fatigable ptosis (drooping of the eyelids), ophthalmoplegia (eye muscle weakness), and diplopia (double vision). On the other hand, postpubertal patients tend to develop generalized weakness more frequently. In the prepubertal group, approximately half of the cases manifest solely as ocular symptoms, which is higher than adult MG cases. In generalized cases, additional symptoms may include facial weakness, dysarthria (difficulty speaking), and dysphagia (difficulty swallowing). In severe cases known as myasthenic crises, respiratory muscles may be affected, posing a life-threatening situation requiring respiratory support. It is uncommon for juvenile MG to be associated with the development of thymoma, a thymus gland tumor. The exact underlying mechanisms causing MG are not fully understood. However, the disease is thought to be related to specific antibodies against various muscle receptors, predominantly the acetylcholine receptor (AChR) and, less commonly, the muscle-specific receptor tyrosine kinase (MuSK). Severe cases may be life-threatening, but the prognosis is generally good. In the prepuberal form, there is a higher remission rate in patients with the ocular form.

• The estimated incidence of juvenile myasthenia gravis in the United States is 1.2 per million person-years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: